Mayne Pharma Group (Mayne Pharma Group) FCF Margin % : -23.99% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Mayne Pharma Group FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Mayne Pharma Group's Free Cash Flow for the six months ended in Dec. 2023 was $-30.1 Mil. Mayne Pharma Group's Revenue for the six months ended in Dec. 2023 was $125.3 Mil. Therefore, Mayne Pharma Group's FCF Margin % for the quarter that ended in Dec. 2023 was -23.99%.

As of today, Mayne Pharma Group's current FCF Yield % is -9.08%.

The historical rank and industry rank for Mayne Pharma Group's FCF Margin % or its related term are showing as below:

MAYNF' s FCF Margin % Range Over the Past 10 Years
Min: -192.25 Med: -4.01 Max: 11.53
Current: -12.65

During the past 13 years, the highest FCF Margin % of Mayne Pharma Group was 11.53%. The lowest was -192.25%. And the median was -4.01%.

MAYNF's FCF Margin % is ranked worse than
72.07% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 0.265 vs MAYNF: -12.65

Mayne Pharma Group FCF Margin % Historical Data

The historical data trend for Mayne Pharma Group's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group FCF Margin % Chart

Mayne Pharma Group Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

4.71

11.53

8.43

-4.50

-143.81

Mayne Pharma Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-2.65	-6.08	-271.41	13.26	-23.99

Competitive Comparison of Mayne Pharma Group's FCF Margin %

For the Drug Manufacturers - General subindustry, Mayne Pharma Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mayne Pharma Group's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's FCF Margin % falls into.

Mayne Pharma Group FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Mayne Pharma Group's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-176.038	/	122.409
	=	-143.81 %

Mayne Pharma Group's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-30.063	/	125.297
	=	-23.99 %

Mayne Pharma Group FCF Margin % Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mayne Pharma Group (Mayne Pharma Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (OTCPK:MAYNF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

HG6:Germany MYX:Australia

Address

1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106

Website

http://www.maynepharma.com

Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.